This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nuffield Council on Bioethics. Pharmacogenetics: Ethical Issues. Nuffield Council on Bioethics: London, 2003.
Rippe KP, Bachmann A, Faisst K, Oggier W, Pauli-Magnus C, Probst-Hensch N et al. (TA SWISS): Pharmakogenetik und Pharmakogenomik. TA 48/2004. Bern 2004.
European Commission. Ethical, Legal and Social Aspects of Genetic Testing: Research, Development and Clinical Applications. Report of the STRATA Expert Group: Brussels, 2004.
Mahlknecht U, Voelter-Mahlknecht S . Pharmacogenomics: questions and concerns. Curr Med Res Opin 2005; 21: 1041–1047.
van Delden J, Bolt I, Kalis A, Derijks J, Leufkens H . Tialor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18: 303–321.
Netzer C, Biller-Andorno N . Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 2004; 18: 344–360.
Smart A, Martin P, Parker M . Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 2004; 18: 322–343.
Schubert L . Ethical implications of pharmacogenetics – do slippery slope arguments matter? Bioethics 2004; 18: 361–378.
Lee S . Racializing drug design: implications of pharmacogenomics for health disparities. Am J Public Health 2005; 95: 2133–2138.
Mackenzie R . Reprogenetics and pharmacogenetics: in whose best interests? Med Law 2005; 24: 343–354.
La Caze A . Does pharmacogenomics provode and ethical challenge to the utilisation of cost-effectiveness analysis by public health systems? Pharmacoeconomics 2005; 23: 445–447.
Marx-Stoelting L . Pharmakogenetik. LIT: Muenster, 2006 accepted.
Beauchamp TL, Childress JF . Principles of Biomedical Ethics, 5th edn. Oxford University Press: Oxford, 2001.
Schmedders M, Aken Jv, Feuerstein G, Kollek R . Individualized pharmacogenetic therapy: a critical analysis. Community Genet 2003; 6: 114–119.
Kollek R, Feuerstein G, Schmedders M, van Aken J . Pharmakogenetik: Implikationen für Patienten und Gesundheitswesen: Anspruch und Wirklichkeit der ‘individualisierten Medizin’. Nomos: Baden-Baden, 2004.
Gurwitz D, Lunshoff JE, Dedoussis G, Flordellis CS, Fuhr U, Kirchheiner J et al. Pharmacogenomics education: international society of pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenom J 2005; 5: 221–225.
Frueh FW, Goodsaid F, Rudman A, Huang SM, Lesko LJ . The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenom J 2005; 5: 218–220.
Melzer D, Raven A, Detmer DE, Ling T, Zimmern RL . My Very Own Medicine: What Must I Know? Information Policy for Pharmacogenetics 2003.
Morley KI, Hall WD . Using pharmacogenetics and pharmacogenomics in the treatment of pychiatric disorders: some ethical and economical considerations. J Mol Med 2004; 82: 21–30.
Lindpaintner K . Pharmacogenetics and the future of medical practice: conceptual considerations. Pharmacogenomics 2001; 1: 23–26.
Green MJ, Botkin JR . ‘Genetic Exceptionalism’ in medicine: clarifying the differences between genetic and nongenetic tests. Ann Internal Med 2003; 138: 571–576.
Freund CL, Clayton EW . Pharmacogenomics and children: meeting the ethical challenges. Am J Pharmacogenom 2003; 3: 309–404.
Acknowledgements
I would like to thank Philip and David Marx-Stöelting, Professor Eve-Marie Engels and Professor Vera Hemleben for their support and the Heinrich-Böell-Foundation for funding.
Author information
Authors and Affiliations
Corresponding author
Additional information
Duality of Interest
None declared
Rights and permissions
About this article
Cite this article
Marx-Stölting, L. Pharmacogenetics and ethical considerations: why care?. Pharmacogenomics J 7, 293–296 (2007). https://doi.org/10.1038/sj.tpj.6500425
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500425
This article is cited by
-
Attitudes of Health Care Professionals Toward Pharmacogenetic Testing
Molecular Diagnosis & Therapy (2011)